KDM4C and prostate carcinoma: Various studies have shown that, JMJD2C was overexpressed in prostate cancers and promoted abnormal activation of AR (androgen receptor) targeting genes such as kallikrein-related peptidase 2 (KLK2) and prostate-specific antigen (PSA), and both of which had the important function to cleave proteins that affecting cell proliferation and metastasis.